AGIO Overview
Upcoming Projects (AGIO)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (AGIO)
-
Exploring Agios Pharma's Phase 3 ENERGIZE Study of Mitapivat for Non-Transfusion-Dependent Thalassemia
Ticker: AGIO
Executed On: Jul 12, 2024 at 09:00 AM EDT -
Discussing new therapies for the treatment of sickle cell disease with a hematologist.
Tickers: AGIO, PFE
Executed On: Apr 02, 2024 at 10:00 AM EDT -
Exploring the Breakthroughs of Mitapivat in Non-Transfusion-Dependent Alpha- or Beta-Thalassemia: Insights from the Phase 3 ENERGIZE Study
Ticker: AGIO
Executed On: Feb 06, 2024 at 01:30 PM EST -
Digging into Agios Pharmaceuticals Phase 2a study of AG-946 for treatment of adult patients with Anemia due to Lower-Risk Myelodysplastic Syndromes (LR-MDS).
Ticker: AGIO
Executed On: Nov 28, 2023 at 12:00 PM EST -
Digging into the Phase 2 RISE UP data on Agio's PYRUKYND (mitapivat) in patients with sickle cell disease
Ticker: AGIO
Executed On: Aug 03, 2023 at 10:00 AM EDT
Expired Projects (AGIO)
-
Examining Agios Pharmaceuticals'(AGIO) Recent Phase 3 ACTIVATE-KidsT Study Results for Mitapivat in Pediatric PK Deficiency
Ticker: AGIO
Execute By: Oct 31, 2024 -
Discussing Agios’ Mitapivat (pyruvate kinase R activator) in Adult PK Deficiency following June 2022 Phase 3 ACTIVATE analysis
Ticker: AGIO
Execute By: Jul 31, 2022
Upcoming & Overdue Catalysts (AGIO)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (AGIO)
-
Agios (AGIO) Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO (ivosidenib tablets) in Patients with Previously Treated IDH1-
Ticker: AGIO
Occurred on: Jan 17, 2021 -
Agios' (AGIO) Phase 1 TIBSOVO (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML) Translational Data Released
Ticker: AGIO
Occurred on: Dec 09, 2019 -
Phase 1 updated data of Agios'(AGIO) ivosidenib in IDH1 mutant newly diagnosed AML ineligible for standard therapies presented at ASCO
Ticker: AGIO
Occurred on: Jun 03, 2019 -
Agios Pharma (AGIO) to complete Phase 1 Study of AG-881 in patients with Hematologic Malignancies With an IDH1 or IDH2 Mutation in Q1 2018
Tickers: AGIO, CELG
Occurred on: Jun 01, 2018 -
Agios Pharma (AGIO) to complete Phase 2 study of AG-348 in Patients With Pyruvate Kinase Deficiency in Q3 2017
Ticker: AGIO
Occurred on: Dec 12, 2017 -
Agios Pharma (AGIO) to complete Phase 1/2 Study of AG-221 in Subjects with Hematologic Malignancies with an IDH2 Mutation in September 2017
Tickers: AGIO, CELG
Occurred on: Jun 24, 2017 -
Agios Pharma (AGIO) to Complete Phase 1 study of AG-120 in Subjects With Advanced Solid Tumors with an IDH1 Mutation in August 2017
Tickers: AGIO, CELG
Occurred on: Jun 03, 2017 -
Agios Pharma (AGIO) to complete Phase 1 study of AG-519 in Patients With Pyruvate Kinase Deficiency in September 2016
Ticker: AGIO
Occurred on: Jun 09, 2016 -
Agios Pharma (AGIO) data from Phase 1 trial of AG-120 underwhelms investors
Tickers: AGIO, CELG
Occurred on: Nov 09, 2015
Strategic Initiatives (AGIO)
-
Celgene (CELG) and Agios (AGIO) Ink Collaboration Agreement with Abbott (ABT) to Develop and Commercialize Companion Diagnostic Tests for Certain Leukemia Patients
Tickers: CELG, ABT, AGIO
Announcement Date: Oct 12, 2016 -
Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights from 2010 Agreement
Tickers: CELG, AGIO
Announcement Date: May 17, 2016
